# Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease

> **NCT04765423** · NA · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Malignant Neoplasm of Prostate

## Interventions

- **DEVICE:** [F-18] NaF PET/CT
- **DEVICE:** [F-18] fluciclovine PET/CT

## Key facts

- **NCT ID:** NCT04765423
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-03-25
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-03-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor patient accrual
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04765423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04765423, "Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04765423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*